AGH 3.06 0.00 Vol 0 AGL 22 0.00 Vol 0 BAS 1.5 0.00 Vol 0 BFM 17.05 0.00 Vol 0 BG23B 97.4999 0.00 Vol 0 BPH 6.4 0.00 Vol 0 DEVON 3.95 0.00 Vol 0 LOM 2.77 0.00 Vol 0 NTB 36.25 0.25 Vol 2500 ONE 3.5 0.00 Vol 0 POLAR 8 0.00 Vol 0 SOM 15.3 0.00 Vol 0 WHHL 3.75 0.00 Vol 0 WWW 21.5 0.00 Vol 0
Market Closed:

Jazz Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference

Hamilton, Bermuda – 08 March 2019 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX announced its participation the Cowen and Company Conference.  The filing stated:


DUBLIN, March 5, 2019 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that thecompany will be webcasting its corporate presentation at the Cowen and Company 39th AnnualHealthcare Conference in Boston, MA.


Matt Young, executive vice president and chief financial officer, will provide an overview of thecompany and a business and financial update at the conference on Tuesday, March 12, 2019 at12:00 p.m. EDT/ 4:00 p.m. GMT.


A live audio webcast of the presentation may be accessed from the Investors section of the JazzPharmaceuticals website at Please connect to the website prior tothe start of the presentation to ensure adequate time for any software downloads that may benecessary to listen to the webcast.


An archive of the webcast will be available for at least one week following the presentation on theInvestors section of the company’s website at


About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated todeveloping life-changing medicines for people with limited or no options. As a leader in sleepmedicine and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio of productsand product candidates in development, and is focused on transforming biopharmaceuticaldiscoveries into novel medicines. Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oralsolution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) andVyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase®,Defitelio® (defibrotide) and Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion incountries outside the U.S. For country-specific product information, please visit For more information, please and follow us on Twitter at @JazzPharma.



Jazz Pharmaceuticals Contacts:


Kathee Littrell

Vice President, Investor RelationsIreland, +353 1 634 7887

U.S., +1 650 496 2717



Jacqueline Kirby

Vice President, Corporate Affairs & Government RelationsIreland, +353 1 697 2141

U.S., +1 215 867 4910


08:30-09:00 Price Discovery
09:00-16:30 Continuous Trading


TEL: +1 (441) 292 7212
FAX: +1 (441) 292 7619


30 Victoria Street
3rd Floor
Hamilton, Bermuda


P.O. Box HM 1369
Hamilton HMFX



The information contained in these pages has been obtained from sources which The Bermuda Stock Exchange believes are reliable. However, the accuracy of the information cannot and is not guaranteed and The Bermuda Stock Exchange makes no representation as to its accuracy or completeness. Neither this Web site, nor any information contained herein, constitutes advice or a solicitation to subscribe, purchase or sell any securities. The Bermuda Stock Exchange expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon any part of the contents of this site or any external sites referenced from this website.